Wilmington Savings Fund Society FSB Cuts Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Wilmington Savings Fund Society FSB cut its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,002 shares of the medical research company’s stock after selling 745 shares during the period. Wilmington Savings Fund Society FSB’s holdings in IQVIA were worth $1,769,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Capital Performance Advisors LLP bought a new position in shares of IQVIA in the 3rd quarter valued at about $27,000. Avior Wealth Management LLC lifted its stake in shares of IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the last quarter. Synergy Asset Management LLC purchased a new position in shares of IQVIA in the 4th quarter worth approximately $33,000. Assetmark Inc. increased its position in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares during the last quarter. Finally, UMB Bank n.a. lifted its position in IQVIA by 74.4% in the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after buying an additional 99 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 0.9 %

NYSE:IQV opened at $208.13 on Monday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84. The stock has a market capitalization of $37.78 billion, a P/E ratio of 27.75, a P/E/G ratio of 2.25 and a beta of 1.48. The company’s 50-day simple moving average is $200.67 and its 200-day simple moving average is $219.40. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 10.81 earnings per share for the current fiscal year.

Insider Buying and Selling at IQVIA

In related news, Director John G. Danhakl purchased 1,275 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the purchase, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

IQV has been the topic of several recent analyst reports. Robert W. Baird reduced their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. UBS Group dropped their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a report on Wednesday, December 11th. The Goldman Sachs Group dropped their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, TD Cowen reduced their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $252.39.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.